Swiss National Bank Sells 7,600 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Swiss National Bank lessened its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,500 shares of the specialty pharmaceutical company’s stock after selling 7,600 shares during the quarter. Swiss National Bank’s holdings in Collegium Pharmaceutical were worth $2,108,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its stake in Collegium Pharmaceutical by 320.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after acquiring an additional 2,877 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Collegium Pharmaceutical by 28.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company’s stock worth $272,000 after purchasing an additional 1,967 shares during the last quarter. Versor Investments LP purchased a new stake in Collegium Pharmaceutical in the 3rd quarter valued at about $207,000. Ritholtz Wealth Management purchased a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $286,000. Finally, Everence Capital Management Inc. purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $302,000.

Collegium Pharmaceutical Stock Up 1.3 %

COLL stock opened at $34.25 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The stock has a fifty day moving average of $36.84 and a 200-day moving average of $33.02. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of 14.27 and a beta of 1.06. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The firm had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. As a group, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the sale, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.98% of the stock is owned by insiders.

Wall Street Analyst Weigh In

COLL has been the subject of a number of research analyst reports. Needham & Company LLC downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Truist Financial raised their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, February 26th. Piper Sandler downgraded shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target on the stock. in a report on Friday, May 10th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $39.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.